A Cancer Chemotherapy Drug Is in Short Supply — What Carboplatin Patients Should Know

The short version: The FDA has listed carboplatin injection as currently in shortage. This is a platinum-based chemotherapy drug used to treat several common cancers, including ovarian cancer, non-small cell lung cancer, and testicular cancer. The shortage has been an ongoing problem since at least 2023, affecting cancer centers across the country. Patients and families need to know what questions to ask and what their rights are if treatment is delayed or changed without their full understanding.

What Carboplatin Is and What It Treats

Carboplatin is a chemotherapy drug that has been used to fight cancer since the FDA first approved it in 1989. It belongs to a class of drugs called platinum-based agents, which work by interfering with cancer cells' ability to grow and divide. It is considered a cornerstone treatment for several types of cancer.

The most common cancers treated with carboplatin include:

• Ovarian cancer — carboplatin is one of the primary first-line chemotherapy options
• Non-small cell lung cancer — often used in combination with other drugs
• Testicular cancer — used when other treatments have not worked
• Head and neck cancers
• Endometrial and cervical cancers
• Brain tumors

Carboplatin is almost always given as an intravenous infusion, meaning it is delivered directly into the bloodstream through an IV at a hospital or infusion center. Because it is a generic drug made by multiple manufacturers, patients do not always receive the same brand or formulation — which means shortages at one manufacturer can ripple through the entire supply chain.

What a Drug Shortage Means in Practice for a Cancer Patient

When a commonly used drug shows up on the FDA shortage list, it does not automatically mean every hospital is out of supply. But it does mean that the overall supply is not meeting demand — and that cancer centers are having to make difficult decisions.

In practice, a carboplatin shortage can mean any of the following:

• Your treatment is delayed while your care team waits for supply to arrive
• Your dose is reduced because the center is rationing what it has
• You are switched to a different drug — such as cisplatin — that may not behave the same way in your body for your specific cancer
• Your treatment schedule is changed in ways that affect how effective it can be

Any of these changes can feel alarming when you are in the middle of cancer treatment. It is important to know that your care team should be explaining any changes to you — what they are switching you to, why, and what the expected outcome is. If they are not giving you that information clearly, you have every right to ask.

The Broader Chemotherapy Drug Supply Problem

Carboplatin is not the only cancer drug that has been in short supply. Cisplatin — another platinum-based chemotherapy drug and one of the most widely used cancer treatments in the world — also experienced a significant shortage beginning in 2022 and 2023. At the height of that shortage, the American Society of Clinical Oncology issued emergency guidance to oncologists on how to manage reduced access to both drugs.

The root causes of these shortages are complicated, but they come down to a few key factors. Many chemotherapy drugs are generics, which means manufacturers compete on price and operate on thin margins. That leaves little financial incentive to maintain large stockpiles or redundant production capacity. When a single large manufacturer has a production problem — equipment failure, contamination, a quality issue — the entire market can feel the impact almost immediately.

The concentration of manufacturing is also a factor. A significant share of the world's supply of several chemotherapy drugs comes from a small number of factories, many of them outside the United States. When those factories run into trouble, American patients feel it.

What to Ask Your Oncologist

If you are currently receiving carboplatin as part of your cancer treatment, here are the most important questions to bring to your next appointment:

• Do you currently have the carboplatin I need for my upcoming infusion? Ask specifically for your scheduled date.
• If there is a supply issue, what is the plan? Will there be a delay, a dose adjustment, or a switch to another drug?
• If I am switched to a different drug, how does it compare to carboplatin for my specific type and stage of cancer?
• Will any change to my treatment plan affect my prognosis or the expected outcome?
• Can you document this conversation and the reason for any changes in my medical record?

Your oncologist should be willing to answer all of these questions directly. If you feel like you are not getting clear answers, ask to speak with a patient advocate at your treatment facility. Every major cancer center has one.

When a Shortage Becomes a Serious Problem

Most patients who experience a supply disruption during cancer treatment will have it managed appropriately by their care team. But not everyone does. There are situations where a shortage can cross the line into something more serious — and where the people responsible for ensuring adequate drug supply may have more to answer for.

That may be the case if:

• Your treatment was delayed for a significant period and your cancer progressed during that time
• You were switched to a different drug without being told clearly why or what the risks were
• The substitute drug caused complications or side effects that carboplatin was not expected to cause
• Your care team documented a supply problem but did not take adequate steps to find alternatives

If something like this happened to you or a family member, it is worth asking questions. A lawyer who handles cases like this can review your medical records and the timeline of events at no cost to you and tell you whether what happened rises to the level of something that can be addressed through the legal system.